We use a few cookies

Essential cookies keep the library working. With your permission, we'd also like to use analytics to see what's useful and improve the experience. Read our Privacy Policy or Cookie Policy.

Skip to main content
Home/e-Resources/Medical Sciences/IDO2: A Pathogenic Mediator of Inflammatory Autoimmunity
PeriodicalsMedical Sciences

IDO2: A Pathogenic Mediator of Inflammatory Autoimmunity

Checking your access to this record.

Abstract & Overview

Indoleamine 2,3-dioxygenase 2 (IDO2), a homolog of the better-studied tryptophan-catabolizing enzyme IDO1, is an immunomodulatory molecule with potential effects on various diseases including cancer and autoimmunity. Here, we review what is known about the direct connections between IDO2 and immune function, particularly in relationship to autoimmune inflammatory disorders such as rheumatoid arthritis and lupus. Accumulating evidence indicates that IDO2 acts as a pro-inflammatory mediator of autoimmunity, with a functional phenotype distinct from IDO1. IDO2 is expressed in antigen-presenting cells, including B cells and dendritic cells, but affects inflammatory responses in the autoimmune context specifically by acting in B cells to modulate T cell help in multiple model systems. Given that expression of IDO2 can lead to exacerbation of inflammatory responses, IDO2 should be considered a potential therapeutic target for autoimmune disorders.

Cite this record

Lauren M.F. Merlo, Laura Mandik‐Nayak (2016). IDO2: A Pathogenic Mediator of Inflammatory Autoimmunity. Clinical Medicine Insights Pathology, 9s1(Suppl 1), 21–28. https://doi.org/10.4137/cpath.s39930

Copy in another style

Merlo, L. M., & Mandik‐Nayak, L. (2016). IDO2: A Pathogenic Mediator of Inflammatory Autoimmunity. Clinical Medicine Insights Pathology, 9s1(Suppl 1), 21–28. https://doi.org/10.4137/cpath.s39930
Author names are used as deposited, so check their order before you submit.

Metadata is harvested from open-access indexes and can be incomplete. Check a citation against the published version before relying on it — see our open access & attribution policy.